Background: Diastolic heart failure (DHF) accounts for over 40% of HF cases. Proven evidence based treatment is lacking. A novel mechanical approach, utilizing energy exerted by the left ventricle (LV) during systole and returning it to the ventricle during diastole to enhance diastolic performance, was realized in two approachs: An Extraventricular device (ImCardia™), comprised of elastic springs attached to the LV epimyocardium. A trans apically delivered Intra-ventricular device (CORolla™) comprised of a three-arms spring. Methods: The ImCardia™ device was implanted as an add-on to AVR (study group, n=10), and compared to AVR only (control group, N=9). The patients were followed up to 24 months to examine indications of safety and efficacy. The CORolla™ device was implanted off-pump in trans-apical approach in healthy sheep (N=26). The sheep were followed up to 9 months. Device acute and chronic safety was evaluated. Results: ImCardia™: During follow-up period there were no device-related complications or adverse events. Improvement in NYHA functional class, 6-minute walk test and quality of life were similar for both groups. LV mass regression after 18-24 months: -90 gr ± 82 gr in control group Vs -126 gr ± 33 gr in study group. Left atrial area, an important marker of diastolic dysfunction, increased slightly in control group (+1.5 cm2 ± 4.09 cm2) but decreased in study group (-2.29 cm2 ± 3.09 cm2). CORolla™: good recuperation post implantation with no weight reduction, no EF reduction, good device functionality and safety in follow-up up to 9 months. Conclusion: A passive extra-cardiac device which transfers energy from systole to diastole, may improve diastolic performance as suggested by further decrease in left atrial size beyond that expected from AVR only; not only the device did not induce LV hypertrophy, it rather demonstrated a trend of LV mass regression enhancement. Using this methodology, an Intra-ventricular elastic device implanted transapically off-pump demonstrated safe profile. Clinical study is planned to start toward end 2011. Percutaneous approach for the intra-ventricular device is in R&D process. 
Background:
To investigate the potential benefit of Impella 2.5 in high-risk PCI (HRPCI) compared to the intra-aortic balloon-pump (IABP) in a prospective multicenter clinical trial. Methods: The PROTECT II trial was designed to randomize 654 HRPCI patients who required prophylactic hemodynamic support to Impella or IABP. Patients with 3-vessel disease and LV ejection fraction (LVEF) ≤30%, or with unprotected left main or last patent conduit and LVEF ≤35% were eligible for enrollment. Selection of the revascularization approach was at the discretion of the PCI operator. The primary endpoint was a composite of 10 major adverse events (MAE) at 30 days with a followup at 90 days. Results: Enrollment began in late 11/2007 and reached the 50% mark (n=327) by 02/2010. After pre-specified review of the 50% enrollment data, the Data Safety Monitoring Board recommended termination of the study due to futility on the 30-day primary analysis. At the time of the recommendation (11/2010), the study had reached 68% of the planned enrollment (N=447). The preliminary analysis showed a significant learning curve with Impella, with outcomes improving over the course of the trial. There was a trend for better outcomes at 30 days in favor of Impella for the entire per protocol population (p=0.10). At the 90-day pre-specified follow-up, there was a significant reduction in MAE in favor of Impella (p=0.03, see Figure) . The final new clinical and angiographic results of the entire cohort will be presented.
Conclusion:
PROTECT II was terminated early on assumptions based on the first half of the data. The analysis of the full cohort provides more insight into the study and suggests positive outcomes over time for the Impella compared to the IABP with a similar safety profile. Background: Recent studies of patients who have been resuscitated from out-ofhospital cardiac arrest (OHCA) have shown increasing benefit from timely reperfusion therapy for those with STEMI as the etiology. Though no randomized trials have been performed, patients with OHCA with early reperfusion for concurrent STEMI have a mean survival rate of 65%, compared to historical survival of only 25% to 35% for those with only OHCA. The addition of early hypothermia to early reperfusion results in significantly improved neurological function. We reviewed our data to see if OHCA patients who do not fit these criteria were undergoing urgent angiography inappropriately. Methods: Our facility is a large, academic, community center with around-the-clock catheterization capabilities for STEMI. We retrospectively examined our internal databases of consecutive patients suspected of having STEMI between January 1, 2001 and December 31, 2010. Further data was obtained from electronic hospital records, emergency department records, paramedic records, and the cardiac catheterization database. Results: Between January 1, 2001 and December 31, 2010, there were 3908 consecutive patients who were suspected of having an MI, 409 of which required CPR. Of these, 240 underwent emergent angiography. In 191 patients a culprit lesion was identified, but in 49 (20%) no culprit lesion was seen. Review of the pre-cath EKGs showed no definitive ST-elevation in 26 of 49 patients (53%). Ventricular fibrillation or tachycardia was the presenting rhythm in 34 patients (69%). During their hospitalization, 26 patients (53%) died. Conclusion: Even though the favorable outcomes in the available literature are based on STEMI concurrent with OHCA, a significant number of patients who do not have ST-elevation on post-resuscitation EKG are undergoing cardiac angiography emergently. Other measures such as stabilizing hemodynamics, controlling rhythms, and, perhaps most importantly, early initiation of hypothermia are probably more important at this stage when the EKG does not show ST-elevation. 
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≤ 30% or with unprotected left main/last patent conduit and LV ejection fraction ≤ 35% during PCI. Patients were randomized to either intra aortic balloon pump (IABP) or Impella (Abiomed). The primary endpoint was a composite of ten major adverse events (MAE) measured at 30 and 90 days. Economic analyses were performed to assess resource utilization for patients treated with Impella compared to IABP from index stay up to 90 days. Itemized hospital bills were collected for U.S. patients that consented for the economic study (N=260), converted to costs using department level cost-to-charge ratios, and modeled for the complete trial patient population at 90 days. Estimated costs were validated via comparison with MedPAR. Measures of episodeof-care costs, major adverse cardiac and cerebral events (MACCE), and Quality-Adjusted Life Years (QALYs) for both study arms served as inputs to a Markov model to estimate the incremental cost-effectiveness ratio (ICER). Results: MAE at 90 days for Impella were 40.8% vs. IABP 51.4% (p=0.029) including a 51% relative reduction in repeat revascularization (Impella 6.1% vs. IABP 12.4%, p=0.026). For the economic study, index hospital costs were lower in the IABP arm while readmission costs and length of stay were lower in the Impella arm. Median hospital days for entire episode-of-care for Impella were 7 days vs. IABP 9 days (p=0.048). Reduction in MAE was associated with a gain in QALY for Impella patients. Base case ICER was well below the $100,000 value often given as a threshold for innovative technologies. Conclusion: For patients with severe LV dysfunction and complex anatomy, prophylactic use of Impella during PCI reduced MAE at an incremental cost per quality-adjusted life year considered to be cost-effective for advanced cardiovascular technologies. Reductions in repeat revascularizations, readmission costs and length of stay may have significant health policy implications.
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Aspiration of The Blood From The Left Ventricular cavity to Treat Refractory Ventricular Arrhythmias During Complex Coronary Interventions
Waleed Y Kadro, Maya Turekmani, Hussam Rahim, Ali Dbs, Ismael Eid Interventional Cardiology, The Golden Cardiovascular Center, Damascus, Syrian Arab Republic
Background: Ventricular fibrillation (VF) may happen during complex coronary intervention due to wire or catheter manipulation, balloon inflation or reaction to the contrast. This can be treated easily with prompt cardioversion; however some of VF may become refractory especially in the cases of severe ischemic burden, elevated left ventricular filling pressure (LVEDP) or reduced left ventricular function. Methods: We report a new simple quick method to reduce LVEDP by inserting a catheter (e.g a pigtail or JR) inside the left ventricle (LV) and doing quick manual aspiration of 80-100cc of blood from the LV cavity. This will quickly reduce the LVEDP and make refractory VF easily responsive to cardio version. It can also provide a simple decompression of the overfilled LV after prolonged circulatory arrest. Results: This method was used in 8 cases of refractory VF. Five of them failed 3 attempts of DC cardioversion despite recanulization of the diseased artery. After doing this maneuver, those five cases responded immediately to the next attempt of cardioversion. Three other cases of VF responded to cardioversion with electrical sinus rhythm however the 3 patients remained pulseless in electromechanical dissociation (EMD), no arterial pressure and no cardiac movement on fluoroscopy. Despite ruling out tamponade and mechanically treating cardiac ischemia the two patients remained in EMD. After doing the pigtail maneuver EMD resolved and active cardiac movement were seen on fluoroscopy with acceptable arterial pressure recovery. All of these 8 patients survived till hospital discharge. Conclusion: Quick insertion of a catheter in the LV with quick blood aspiration facilitates response to cardioverion and may relief EMD not related to tamponade during coronary intervention. It looks that the interventional cardiologists need this simple way of LV venting in the cath lab.
TCT-486 Medical Treatment and Coronary Angioplasty in Patients with Severe Left Ventricular Dysfunction and Coronary Artery Disease
Diego David Grinfeld, Florencia Rolandi, Pablo Pollono, Ignacio Rifourcat, Fernando Fuertes, Jose Luis Parmisano, Ricardo Pastene, Liliana Grinfeld Hospital Espanol de La Plata-Idytac, La Plata, Argentina Background: Background: Coronary artery disease (CAD) is the cause of Ventricular Dysfunction and Heart Failure (HF) in the majority of patients (pts), and HF is the only mode of CAD presentation associated with increasing incidence and mortality. Among a large number of patients there is no evidence about witch therapeutic strategy is better, so a large number of patients how could be beneficiated by a Coronary Angioplasty with Stent (PCI) receive medical treatment. Methods: Methods: Between June 2005 and December 2010 we performed 3450 consecutives coronary angiographies, among those pts 255 (7.4%) have had LVEF<35% and coronary disease. We divide the pts en 2 groups: MT and PCI. Results: Results: population: age 66.8 ± 9.4 years, 84% male, 80.3% hypertension, 35.2% diabetes, 72.9% lipid disorders, 12.8% smokers, 55.6% ex-smokers, 26.5% with familiar history of CAD, 62.3% with previous AMI, 3.1 % previous Stroke, 15.2% previous PCI and 25.6% previous CABG. One out of 5 pts were hospitalized in the last year because of HF. At baseline 46.6% of the pts were in dyspnea FC III-IV; 11.2% in FC I-II and 42.2% were asymptomatics. Only 54 % of the total population received complete Medial Treatment (MT) (bet blockers, enalapril and diuretics). Multivesel disease was present in 55.8% of the pts. CABG were performed in 28 pts (10.9%), PCI in 135 pts (52.9%), in 65 pts a MV PCI was performed. Drug eluting stents (DES) were used in 63.2% of PCI. The others 92 pts (36.1%) continues with MT. Twelve (12) pts received definitive pace-maker and 10 pts. ICD. Total mortality was 13.5%, no significant differences were found among groups. At follow-up pts who underwent PCI showed an statistically significant diminution in dyspnea FC from III-IV to I-II and other symptoms p<0.0001, asymptomatics 5.0% vs. 26.4 at F/U, p 0.002) compared with MT group pts (FC I-II 0% vs. 17.9%, p-y FC III-IV 13.9% vs. 7.7% at FU, p 0.37; asymptomatics 86.1% vs. 74.4% at F/U, p 0.18). In the CABG group asymptomatics pts were 69.2% pre CABG and 63.6% at FU, p 0.8. Conclusion: Conclusion: in pts with severe left ventricular dysfunction (LVEF <35%) and CAD, PCI improved symptoms and there after quality of life and don't increase mortally at long term Follow up. 
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Conclusion:
Infusion of autologous bone marrow cells into the coronary vein is safe and feasible. It is associated with significant improvement in symptoms and functional capacity benefit. Both groups benefited in terms of LVEF improvement and lower ESV. Our data suggest that nIHF patients have a higher LVEF increment than IHF patient and lasting up to 5 years; revealing a high restoration of myocardial dysfunction. Further randomized studies are warranted.
